Dr Sexl speaks with ecancer at EHA 23 about findings implicating modulation of the JAK-STAT pathway in the transition of myelofibrosis to B cell lymphoma.

She describes the mixed signals of the disease transitioning from one to the other, and the existence of a hidden, amplified B cell clone which drives the aggressive lymphoma.

Dr Sexl recommends screening for this clonal population in patients eligible for JAK-STAT inhibition.